Recurrent Mycosis Fungoides (DBCOND0080283)

Identifiers

Synonyms

Mycosis fungoides recurrent / Cutaneous T-cell lymphoma recurrent

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	AFM-13 Acimtamig Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT03075553	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Nivolumab	treatment	2	terminated
NCT03373305	Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas	Brentuximab vedotin Lenalidomide	treatment	1	withdrawn
NCT03432741	Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer	Belinostat Carfilzomib Copanlisib Daratumumab Fludeoxyglucose (18F) Fluorine F-18 Gemcitabine Nivolumab Obinutuzumab Pembrolizumab Rituximab Romidepsin Trastuzumab	treatment	1	suspended
NCT04541017	Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment	Magrolimab Mogamulizumab	treatment	1 / 2	active_not_recruiting
NCT03278782	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin	Pembrolizumab Romidepsin	treatment	1 / 2	active_not_recruiting
NCT02702310	Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides	No drug interventions	Not Available	Not Available	recruiting
NCT03011814	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma	Durvalumab Lenalidomide	treatment	1 / 2	active_not_recruiting
NCT03598998	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	Pembrolizumab Pralatrexate	treatment	1 / 2	active_not_recruiting
NCT03017820	VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	Cemiplimab Cyclophosphamide Human interferon beta Sodium iodide	treatment	1	recruiting
NCT02520791	Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma	No drug interventions	treatment	1	active_not_recruiting